Skip to main content
Top
Published in: European Radiology 6/2016

01-06-2016 | Urogenital

Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference

Authors: H. A. Vargas, A. M. Hötker, D. A. Goldman, C. S. Moskowitz, T. Gondo, K. Matsumoto, B. Ehdaie, S. Woo, S. W. Fine, V. E. Reuter, E. Sala, H. Hricak

Published in: European Radiology | Issue 6/2016

Login to get access

Abstract

Objectives

To evaluate the recommendations for multiparametric prostate MRI (mp-MRI) interpretation introduced in the recently updated Prostate Imaging Reporting and Data System version 2 (PI-RADSv2), and investigate the impact of pathologic tumour volume on prostate cancer (PCa) detectability on mpMRI.

Methods

This was an institutional review board (IRB)-approved, retrospective study of 150 PCa patients who underwent mp-MRI before prostatectomy; 169 tumours ≥0.5-mL (any Gleason Score [GS]) and 37 tumours <0.5-mL (GS ≥4+3) identified on whole-mount pathology maps were located on mp-MRI consisting of T2-weighted imaging (T2WI), diffusion-weighted (DW)-MRI, and dynamic contrast-enhanced (DCE)-MRI. Corresponding PI-RADSv2 scores were assigned on each sequence and combined as recommended by PI-RADSv2. We calculated the proportion of PCa foci on whole-mount pathology correctly identified with PI-RADSv2 (dichotomized scores 1–3 vs. 4–5), stratified by pathologic tumour volume.

Results

PI-RADSv2 allowed correct identification of 118/125 (94 %; 95 %CI: 90–99 %) peripheral zone (PZ) and 42/44 (95 %; 95 %CI: 89–100 %) transition zone (TZ) tumours ≥0.5 mL, but only 7/27 (26 %; 95 %CI: 10–42 %) PZ and 2/10 (20 %; 95 %CI: 0–52 %) TZ tumours with a GS ≥4+3, but <0.5 mL. DCE-MRI aided detection of 4/125 PZ tumours ≥0.5 mL and 0/27 PZ tumours <0.5 mL.

Conclusions

PI-RADSv2 correctly identified 94–95 % of PCa foci ≥0.5 mL, but was limited for the assessment of GS ≥4+3 tumours ≤0.5 mL. DCE-MRI offered limited added value to T2WI+DW-MRI.

Key points

• PI-RADSv2 correctly identified 95 % of PCa foci ≥0.5 mL
• PI-RADSv2 was limited for the assessment of GS ≥4+3 tumours ≤0.5 mL
• DCE-MRI offered limited added value to T2WI+DW-MRI
Literature
1.
go back to reference Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA: Cancer J Clin 64(1):9–29CrossRef Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA: Cancer J Clin 64(1):9–29CrossRef
2.
go back to reference Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, Carroll P, Etzioni R (2014) Overdiagnosis and overtreatment of prostate cancer. Eur Urol 65(6):1046–1055CrossRefPubMedPubMedCentral Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, Carroll P, Etzioni R (2014) Overdiagnosis and overtreatment of prostate cancer. Eur Urol 65(6):1046–1055CrossRefPubMedPubMedCentral
3.
go back to reference Ploussard G, Epstein JI, Montironi R et al (2011) The contemporary concept of significant versus insignificant prostate cancer. Eur Urol 60(2):291–303CrossRefPubMed Ploussard G, Epstein JI, Montironi R et al (2011) The contemporary concept of significant versus insignificant prostate cancer. Eur Urol 60(2):291–303CrossRefPubMed
4.
go back to reference Polascik TJ, Passoni NM, Villers A, Choyke PL (2014) Modernizing the diagnostic and decision-making pathway for prostate cancer. Clin Cancer Res 20(24):6254–6257CrossRefPubMed Polascik TJ, Passoni NM, Villers A, Choyke PL (2014) Modernizing the diagnostic and decision-making pathway for prostate cancer. Clin Cancer Res 20(24):6254–6257CrossRefPubMed
7.
go back to reference Wibmer A, Hricak H, Gondo T, Matsumoto K, Veeraraghavan H, Fehr D, et al. (2015) Haralick texture analysis of prostate MRI: utility for differentiating non-cancerous prostate from prostate cancer and differentiating prostate cancers with different Gleason scores. Eur Radiol. Wibmer A, Hricak H, Gondo T, Matsumoto K, Veeraraghavan H, Fehr D, et al. (2015) Haralick texture analysis of prostate MRI: utility for differentiating non-cancerous prostate from prostate cancer and differentiating prostate cancers with different Gleason scores. Eur Radiol.
8.
go back to reference Hamoen EH, de Rooij M, Witjes JA, Barentsz JO, Rovers MM (2015) Use of the Prostate Imaging Reporting and Data System (PI-RADS) for Prostate Cancer Detection with Multiparametric Magnetic Resonance Imaging: A Diagnostic Meta-analysis. Eur Urol 67(6):1112–1121CrossRefPubMed Hamoen EH, de Rooij M, Witjes JA, Barentsz JO, Rovers MM (2015) Use of the Prostate Imaging Reporting and Data System (PI-RADS) for Prostate Cancer Detection with Multiparametric Magnetic Resonance Imaging: A Diagnostic Meta-analysis. Eur Urol 67(6):1112–1121CrossRefPubMed
9.
go back to reference Vache T, Bratan F, Mege-Lechevallier F, Roche S, Rabilloud M, Rouviere O (2014) Characterization of prostate lesions as benign or malignant at multiparametric MR imaging: comparison of three scoring systems in patients treated with radical prostatectomy. Radiology 272(2):446–455CrossRefPubMed Vache T, Bratan F, Mege-Lechevallier F, Roche S, Rabilloud M, Rouviere O (2014) Characterization of prostate lesions as benign or malignant at multiparametric MR imaging: comparison of three scoring systems in patients treated with radical prostatectomy. Radiology 272(2):446–455CrossRefPubMed
10.
go back to reference Rosenkrantz AB, Kim S, Lim RP et al (2013) Prostate cancer localization using multiparametric MR imaging: comparison of Prostate Imaging Reporting and Data System (PI-RADS) and Likert scales. Radiology 269(2):482–492CrossRefPubMed Rosenkrantz AB, Kim S, Lim RP et al (2013) Prostate cancer localization using multiparametric MR imaging: comparison of Prostate Imaging Reporting and Data System (PI-RADS) and Likert scales. Radiology 269(2):482–492CrossRefPubMed
11.
go back to reference Vargas HA, Akin O, Shukla-Dave A, Zhang J, Zheng J, Kanao K, Goldman D, Moskowitz CS, Reuter V, Eastham J, Scardino P, Hricak H (2012) Performance Characteristics of MRI in the Evaluation of Clinically Low-Risk Prostate Cancer: A Prospective Study. Radiology 265(2):478–487CrossRefPubMedPubMedCentral Vargas HA, Akin O, Shukla-Dave A, Zhang J, Zheng J, Kanao K, Goldman D, Moskowitz CS, Reuter V, Eastham J, Scardino P, Hricak H (2012) Performance Characteristics of MRI in the Evaluation of Clinically Low-Risk Prostate Cancer: A Prospective Study. Radiology 265(2):478–487CrossRefPubMedPubMedCentral
Metadata
Title
Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference
Authors
H. A. Vargas
A. M. Hötker
D. A. Goldman
C. S. Moskowitz
T. Gondo
K. Matsumoto
B. Ehdaie
S. Woo
S. W. Fine
V. E. Reuter
E. Sala
H. Hricak
Publication date
01-06-2016
Publisher
Springer Berlin Heidelberg
Published in
European Radiology / Issue 6/2016
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-015-4015-6

Other articles of this Issue 6/2016

European Radiology 6/2016 Go to the issue